MX347844B - Uso del pacap para el tratamiento de infecciones virales en organismos acuaticos. - Google Patents

Uso del pacap para el tratamiento de infecciones virales en organismos acuaticos.

Info

Publication number
MX347844B
MX347844B MX2013006217A MX2013006217A MX347844B MX 347844 B MX347844 B MX 347844B MX 2013006217 A MX2013006217 A MX 2013006217A MX 2013006217 A MX2013006217 A MX 2013006217A MX 347844 B MX347844 B MX 347844B
Authority
MX
Mexico
Prior art keywords
pacap
organisms
infected
viral infections
virus
Prior art date
Application number
MX2013006217A
Other languages
English (en)
Other versions
MX2013006217A (es
Inventor
García Mario Pablo Estrada
González Juana Maria Lugo
González Yamila Carpio
Piñeiro Carolina Tafalla
Original Assignee
Ct Ingenieria Genetica Biotecnologia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotecnologia filed Critical Ct Ingenieria Genetica Biotecnologia
Publication of MX2013006217A publication Critical patent/MX2013006217A/es
Publication of MX347844B publication Critical patent/MX347844B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Abstract

La presente invención se refiere a el uso del polipéptido activador de la adenilato ciclasa de pituitaria (PACAP) para el tratamiento de infecciones virales y enfermedades infecciosas causadas por virus, en organismos acuáticos. El PACAP solo, o combinado con una molécula antiviral, administrado por vía oral, inyección o por baños de inmersión, demuestra su efectividad al aumentar la sobrevida de peces o crustáceos infectados por virus. Además, tras su aplicación se observa que el peso corporal de estos organismos se mantiene igual o aumenta en comparación con el de los organismos infectados y no tratados con dichas preparaciones. Mediante reverso transcripción-reacción en cadena de la polimerasa de tejidos y órganos susceptibles a la infección viral se demuestra que el PACAP o las combinaciones que contengan PACAP, disminuyen la carga viral en los organismos infectados.
MX2013006217A 2010-12-01 2011-11-30 Uso del pacap para el tratamiento de infecciones virales en organismos acuaticos. MX347844B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU20100233A CU20100233A7 (es) 2010-12-01 2010-12-01 Combinación veterinaria para el control de infecciones virales en la acuicultura
PCT/CU2011/000008 WO2012072055A1 (es) 2010-12-01 2011-11-30 Uso del pacap para el tratamiento de infecciones virales en organismos acuaticos

Publications (2)

Publication Number Publication Date
MX2013006217A MX2013006217A (es) 2013-07-15
MX347844B true MX347844B (es) 2017-05-16

Family

ID=45476244

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013006217A MX347844B (es) 2010-12-01 2011-11-30 Uso del pacap para el tratamiento de infecciones virales en organismos acuaticos.

Country Status (19)

Country Link
US (2) US9119830B2 (es)
EP (1) EP2647369B1 (es)
JP (1) JP5997702B2 (es)
KR (1) KR101838721B1 (es)
CN (1) CN103298452B (es)
AR (1) AR084049A1 (es)
AU (1) AU2011335519B2 (es)
BR (1) BR112013013526B1 (es)
CA (1) CA2819206C (es)
CL (1) CL2013001561A1 (es)
CU (1) CU20100233A7 (es)
ES (1) ES2621332T3 (es)
MX (1) MX347844B (es)
MY (1) MY165435A (es)
PT (1) PT2647369T (es)
RU (1) RU2567802C2 (es)
SG (1) SG191823A1 (es)
WO (1) WO2012072055A1 (es)
ZA (1) ZA201304025B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105755014B (zh) * 2016-03-23 2019-03-19 中国科学院水生生物研究所 CaHV-TNFR特异基因及应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5695954A (en) * 1993-05-14 1997-12-09 University Of Victoria Innovation & Development Corporation DNA encoding two fish neuropeptides
CU23557A1 (es) * 2005-11-22 2010-07-20 Ct Ingenieria Genetica Biotech Neuropéptidos para el cultivo de organismos acuáticos

Also Published As

Publication number Publication date
KR20140031840A (ko) 2014-03-13
EP2647369B1 (en) 2017-01-25
CN103298452B (zh) 2016-08-10
CA2819206C (en) 2018-07-10
EP2647369A1 (en) 2013-10-09
CL2013001561A1 (es) 2014-03-21
US20140087998A1 (en) 2014-03-27
BR112013013526B1 (pt) 2020-04-07
US9119830B2 (en) 2015-09-01
US9603900B2 (en) 2017-03-28
AU2011335519B2 (en) 2016-09-22
JP5997702B2 (ja) 2016-09-28
ES2621332T3 (es) 2017-07-03
AR084049A1 (es) 2013-04-17
US20160030519A1 (en) 2016-02-04
KR101838721B1 (ko) 2018-03-14
MX2013006217A (es) 2013-07-15
BR112013013526A2 (pt) 2016-10-18
WO2012072055A1 (es) 2012-06-07
CN103298452A (zh) 2013-09-11
RU2013129830A (ru) 2015-01-10
ZA201304025B (en) 2014-02-26
CU20100233A7 (es) 2012-10-15
SG191823A1 (en) 2013-08-30
JP2013544262A (ja) 2013-12-12
PT2647369T (pt) 2017-04-11
CU23975B1 (es) 2014-01-29
MY165435A (en) 2018-03-22
RU2567802C2 (ru) 2015-11-10
AU2011335519A1 (en) 2013-06-20
CA2819206A1 (en) 2012-06-07

Similar Documents

Publication Publication Date Title
EP2583677A3 (en) Methods for treating HCV comprising at least two direct acting antiviral agent, ribavirin but not interferon.
EA201201235A1 (ru) Комбинации фармацевтических агентов в качестве ингибиторов репликации hcv
ES2527544T1 (es) Tratamiento mono (PSI-7977) o de combinación con AAD para su uso en el tratamiento del VHC
RU2013119607A (ru) Полициклические гетероциклические соединения и способы их применения для лечения вирусных заболеваний
JP2011528713A5 (es)
EA201100390A1 (ru) Соединения для лечения гепатита с
EA201991174A1 (ru) Комбинация двух противовирусных препаратов для лечения гепатита c
EA201291172A1 (ru) Пиразол[1,5-a]пиримидины для противовирусного лечения
EA201000085A1 (ru) dsPHK, ПРЕДНАЗНАЧЕННАЯ ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ИНФЕКЦИИ
RU2010153688A (ru) Режим дозирования телапревира
NZ588655A (en) Treatment of hepatitis c virus infections with telaprevir (vx-950) in patients non-responsive to treatment with pegylated interfer0n-alpha-2a/2b and ribavirin
EA201001748A1 (ru) Соединения, используемые для лечения гепатита с
MX347844B (es) Uso del pacap para el tratamiento de infecciones virales en organismos acuaticos.
EA201001835A1 (ru) Противовирусные соли
RU2015111491A (ru) Комбинация макроциклического ингибитора протеазы hcv, ненуклеозидного ингибитора hcv и ритонавира
RU2013129824A (ru) Новое лечение инфекции вируса гепатита с
TH162735A (th) การใช้ pacap เพื่อรักษาการติดเชื้อไวรัสในสิ่งมีชีวิตในน้ำ
TH162735B (th) การใช้ pacap เพื่อรักษาการติดเชื้อไวรัสในสิ่งมีชีวิตในน้ำ
Dias et al. In-vitro immunomodulatory responses and antiviral activities of antimicrobial peptide octominin against fish pathogenic viruses
JP2014524450A5 (es)
RU2013148539A (ru) Алиспоривир для лечения инфекции вируса гепатита с
CU20110167A7 (es) Composición vacunal que comprende el péptido activador de la adenilato ciclasa de pituitaria como adyuvante molecular.
RU2014116988A (ru) Алиспоривир для лечения инфекции, вызванной вирусом гепатита с
EA201892004A1 (ru) Противовирусные средства для лечения гепатита b
Castilla et al. 24 DHEA Antiviral Properties in Cell Cultures and Animal Models

Legal Events

Date Code Title Description
FG Grant or registration